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Introduction
Probiotic bacteria have the ability to produce exocellular
polymers called exopolysaccharides (EPS). It has been
suggested that the health benefit of probiotic bacteria can
be attributed to the production of EPS. However, the
composition, structure and biological functions of EPS may
vary depending on the type of microorganism and
environmental conditions. Some data suggest that EPS
production is under control of quorum sensing (QS) through
regulation of gene expression for proteins involved in EPS
biosynthesis [1].
EPS is the main substance involved in biofilm formation
and may achieve 50-90% of the total organic substances
such as proteins, lipids and nucleic acids [1]. Bacteria
develop biofilms to protect the microbial community against
environmental stress. It has been established that both
pathogenic, as well as commensal bacteria, generate
biofilms in human mucosas. Biofilm formation is associated
with bacterial infection but it may also play a protective
role. For example, biofilm-like communities of the
gastrointestinal and female urogenital tracts contain
beneficial lactic acid bacteria. It has been shown that the
cell wall components of probiotic bacteria, such as
peptidoglycans or teichoic acids play an important role in
activation of immune cells. By contrast, the role of EPS in
modulation of the immune system is still unclear.
Probiotic bacteria
Probiotics are live microorganisms which exert
a beneficial effects on the host. The Food and Agriculture
Organization of the United Nations defines them as “live
microorganisms which when administered in adequate
amounts confer a health benefit on the host” [2, 3].
Members of genera Lactobacillus and Bifidobacterium are
the most common probiotics used not only for human
consumption [4] but also in pharmaceutical preparations or
in biomedicine [5]. One of the main criteria for selection
of oral administration of probiotics is their ability to adhere
to the intestinal mucosa allowing a transitory colonization
of the gastrointestinal tract [6]. Probiotics maintain the
balance within such complex ecosystem as human intestine
in many ways: inhibition of the proliferation of pathogens
by competition between bacteria and pathogens for
adhesion, suppression of production of virulent factors by
pathogens secreting bacteriocins, or modulation of the host
immune system via interaction between probiotic bacteria
and intestinal epithelial cells [7-9]. However, the
effectiveness of probiotics is strain-specific and each strain
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may affect the host health trough different mechanisms
[10-13]. For instance, lactic acid bacteria (LAB) diminish
symptoms of lactose intolerance, reduce serum cholesterol,
prevent diarrhea, enhance immune responses and anti -
carcinogenic activities, alleviate allergies [14-17]. Lactic
acid bacteria can even prevent or inhibit growth of
pathogenic bacteria [18]. All these effects depend on
adhesion of bacteria and their survival in specific regions
of the gastrointestinal tract, competition with pathogens,
presence of harmful antigens in the environment and
mucosal barrier function.
The idea of using LAB to cure diseases and to promote
health has been existing for at least 100 years, but the
mechanisms of these actions are still poorly understood.
Nevertheless, recent studies show that the probiotic effects
of LAB result not only from whole microorganisms and
cell wall components but also from peptides, nucleic acids
and extracellular polysaccharides produced during growth
of these bacteria [19-21]. It is postulated that this effect is
related to diversity of exopolysaccharide polymers produced
by bacteria [22].
Structure of lactic acid bacteria derived
exopolysaccharides
Almost all LAB have ability to secrete polysaccharide
polymers, which are called exopolysaccharides (EPS).
Lactobacillus, Streptococcus and Lactococcus prevail
mostly among these genera [21-23]. Some strains of
Bifidobacterium are also able to produce EPS [24]. EPS is
secreted in two forms: as a capsular exopolysaccharide
which is associated with the cell surface or as slime
exopolysaccharide secreted as free polymers to the
environment [25, 26]. Chemical structure of EPS has been
studied in details [27-30]. There are over 50 different EPSes
derived from LAB described and they are mostly composed
of repeated units of a certain number of diverse sugar
residues or sugar derivatives [28, 30]. Two main groups of
EPSes are described: homopolysaccharides and hete -
ropolysaccharides (Fig. 1). Structure of EPS depends on
chemical composition. Homopolysaccharides contain
a single type of monosaccharide and it is usually glucose
or fructose. Thus, they are called α-glucans (dextrans) or
fructans. Repeated units consist often of three to eight
monosaccharides. EPS of Streptococcus thermophilus was
the first heteropolysaccharide studied and described in
details [31]. Heteropolysaccharides are composed of at least
two different sugars out of glucose, galactose and rhamnose
at different ratios. The molecular mass of these polymers
ranges between 4.0 × 104 and 6.0 × 106 Da [32]. The
composition and nature of EPS is affected by environmental
conditions, biosynthetic pathways or rate of microbial
growth. Residues such as sn-glycerol-3-phosphate, 
N-acetyl-aminosugars, phosphate and acetyl groups can
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Fig. 1. Examples of primary structure of EPS produced by LAB [28,33]. I: homopolysaccharides: a) dextran, b) levan, c) inulin;
II: heteropolysaccharides: a) Lactobacillus rhamnosus KL37, b) Lactococcus lactis subsp. cremoris NIZO B39, c) Streptococ-
cus thermophilus Sfi32
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also be found [30, 33]. This and the molecular weight
determines the functional properties of EPS [22, 34].
However, not only LAB can produce EPS; some pathogenic
bacteria can synthesize these molecules as well [35, 36].
Biosynthesis and genes 
of exopolysaccharides
All homopolysaccharides are synthesized by extra -
cellular specific enzyme – glycosyl transferase and energy
for this synthesis comes from hydrolysis of sucrose [33].
Heteropolysaccharides are polymers of sugar precursors in
the cytoplasm and several enzymes or proteins are involved
in their synthesis and secretion [37]. The genes for these
enzymes and proteins have been revealed in several strains
of LAB. Genes for EPS synthesis in Lactococcus lactis and
Lactobacillus casei are located in the plasmids [38] 
in contrast to all thermophilic LAB, genes of which 
are located in a bacterial chromosome [33]. There have 
been described sequences of genes for Streptococcus
thermophilus Sfi6 [39, 40], S. thermophilus NCFB 2393
[41] and S. thermophilus MR-1C [42]. Organization of 
these genes appears to be highly conserved [33]. There is
no gene cluster found in Lactobacillus delbrueckii ssp.
bulgaricus so far despite its importance for the production
of fermented products such as yogurts [43].
Biofilm formation – the role 
of exopolysaccharides
There is an increasing interest among researchers
concerning EPS, but the physiological role of these molecules
is still not clear [22, 44, 45]. Most of this research relate to
biofilm formation and its role in bacterial ecology [46, 47].
The term ‘biofilm’ was used for the first time in 1978 by
Costerton et al. [48]. Studies on the role of EPS in biofilm
formation are generally focused on pathogenic bacteria which
are mostly Gram-negative species [49, 50]. Less is known
about EPS in Gram-positive species. EPS fills intracellular
space between bacteria and together with proteins, nucleic
acids and lipids composes the structure of the biofilm matrix.
EPS in biofilm protects bacterial cells from desiccation,
phage attack, antimicrobial compounds, osmotic stress and
predatory attack from protozoa [46, 51-53]. It helps bacteria
to survive in detrimental conditions such as too low or too
high temperature or pH. Capsular polysaccharides can
promote the adherence of bacteria to biological surfaces,
thereby facilitating the colonization of various ecological
niches [25, 30]. EPS also can enable probiotics to survive in
gastric acid and bile salts [19]. Biofilm produced by
pathogenic bacteria makes them less susceptible to antibiotics
and attacks by innate host defense. It plays an important role
in many chronic bacterial infections [54, 55]. Biofilm
formation and EPS production is under control of regulatory
pathway of QS. It has been suggested that QS allows bacteria
to communicate and regulate the expression of genes which
are required for synthesis of EPS in response to changes in
bacteria density [1].
LAB derived exopolysaccharides and the
immune system
Immunomodulating mechanism of LAB is obscure.
However, it has been shown that the cell wall components
of these bacteria, such as peptidoglycan or teichoic acids may
play an important role in activating immune system cells in
the gut [56]. An extract (without peptidoglycan) of cell walls
from Lactobacillus rhamnosus KLC37 containing EPS was
tested in vitro in our laboratory for immunomodulating
capacity. It was compared with lipopolysaccharide (LPS)
from Escherichia coli. It turned out that it stimulated
production of proinflammatory cytokines by mice
macrophages in a dose-dependent manner and this
stimulation depended on p38 and ERK kinase activity.
However, participation of this extract in immunological
response of macrophages was slightly comparable to that of
whole bacteria. Only LPS, but not the extract, could induce
hyporesponsiveness to a subsequent stimulation with LPS.
Interestingly, extract-primed macrophages increased their
ability to bind LPS in studies with atomic force microscopy
[our data, unpublished].
The health benefit of LAB have been attributed to the
production of EPS [25]. LAB EPSes have been claimed to
have immunostimulatory activity [57, 58], antitumor effects
[59, 60] or blood pressure and cholesterol lowering activity
[61, 62]. EPS reduces symptoms of lactose intolerance and
prevents diarrhea [14]. There have been reports that sugar
polymers have antimicrobial properties and help to heal
wounds [63, 64]. It has been also shown that some EPSes
induce cytokine production, act like lymphocytes B mitogens
or change functions of splenocytes [65-67]. EPS can reduce
the symptoms of collagen-induced arthritis or diminish
arteriosclerosis in mice (our research, unpublished). Orally
administrated EPS-producing LAB attenuate severity of
colitis and may be a promising agent in therapy of inflam -
matory bowel disease [7, 68].
In our opinion, such wide diversity of EPS effects on the
immune system results not only from strain specificity, but
also from microenvironmental impact on the EPS metabolism
of probiotic bacteria. However, it is still not clear whether
EPS can be the ligand for pattern recognition receptors and
how the immune system can differentiate pathogenic bacteria
from commensal flora. It is possible that EPS plays a role of
signaling molecule in the mucosal immune system.
Conclusions
EPS is produced by many probiotic bacteria and it is
a key molecule of the biofilm matrix. However, due to the
extreme heterogeneity of EPS, strain specificity and
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unpredictable enzymatic modifications, its immuno -
modulatory potential should be established individually for
each isolated molecule separately. Moreover, the role of EPS
in QS regulation remains to be explained.
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